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Abstract
Background: The treatment goal for recurrent malignant gliomas centers on disease stabilization while minimizing
therapy-related side effects. Metronomic dosing of cytotoxic chemotherapy has emerged as a promising option to
achieve this objective.
Methods: This phase I study was performed using metronomic temozolomide (mTMZ) at 25 or 50 mg/m2/day
continuously in 42-day cycles. Correlative studies were incorporated using arterial spin labeling MRI to assess tumor
blood flow, analysis of matrix metalloproteinase-2 (MMP-2) and MMP-9 activities in the cerebrospinal fluid (CSF) as
surrogates for tumor angiogenesis and invasion, as well as determination of CSF soluble interleukin-2 receptor
alpha (sIL-2Rα) levels as a marker of immune modulation.
Results: Nine subjects were enrolled and toxicity consisted of primarily grade 1 or 2 hematological and
gastrointestinal side effects; only one patient had a grade 3 elevated liver enzyme level that was reversible. Tumor
blood flow was variable across subjects and time, with two experiencing a transient increase before a decrease to
below baseline level while one exhibited a gradual drop in blood flow over time. MMP-2 activity correlated with
overall survival but not with progression free survival, while MMP-9 activity did not correlate with either outcome
parameters. Baseline CSF sIL-2Rα level was inversely correlated with time from initial diagnosis to first progression,
suggesting that subjects with higher sIL-2Rα may have more aggressive disease. But they lived longer when treated
with mTMZ, probably due to drug-related changes in T-cell constituency.
Conclusions: mTMZ possesses efficacy against recurrent malignant gliomas by altering blood flow, slowing
invasion and modulating antitumor immune function.
Keywords: Metronomic temozolomide, Recurrent glioma, Arterial spin labeling, Matrix metalloproteinase,
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Background
Patients with recurrent malignant glioma have poor prog-
nosis. Their respective median progression free survival
(PFS) and overall survival (OS) are 10 and 30 weeks, while
the 6-month PFS is 15% [1]. Although bevacizumab and
tumor treating fields are currently approved treatments,
patient tumors can still progress despite active interven-
tions [2–4]. In particular, patients who failed bevacizumab
almost always exhibit diffusely invasive disease within the
brain. Their respective PFS and OS are 9 and 23 weeks,
and their 6-month PFS is 0% [5]. Therefore, new strategies
that can halt further progression of recurrent gliomas and
neurologic deficits are needed for this population.
Temozolomide (TMZ) is an alkylating chemotherapy
prodrug with activity against recurrent malignant gliomas
[6, 7]. It undergoes spontaneous aqueous conversion to 5-
(3-dimethyl-1-triazenyl)imidazole-4-carboxamide (MTIC)
which then produces diazomethane capable of alkylating
the O6-position of guanine in DNA [8]. The recommended
dosing schedule of 150–200 mg/m2/day for 5 days is based
on a typical phase I dose escalation study with this as the
maximum tolerated dose, and myelosuppression was the
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dose-limiting toxicity [8]. The rationale behind maximum
tolerated dose is to use the highest concentration of chemo-
therapy to directly kill tumor cells, while the patient can
still withstand side effects. Unfortunately, this approach
may interfere with other important antitumor mechanisms
of TMZ. Metronomic temozolomide (mTMZ) schedule
consists of a significantly lower daily dose but at a greater
frequency of administration, typically at 25 or 50 mg/m2/
day on a continuous basis. The biological effect of this
schedule is likely to be different from that of conventional
dosing, and mTMZ has been shown to selectively deplete
CD4+CD25+Foxp3+ regulatory T cells (Tregs), which play
important roles in supporting immunosuppression within
the microenvironment of malignant gliomas [9, 10].
Similar anti-tumor benefits have been observed in metro-
nomic cyclophosphamide, which also alkylates DNA but re-
quires metabolism by the liver for its conversion to
phosphamide mustard that causes DNA cross-linking.
Metronomic cyclophosphamide has been demonstrated to
exert an antiangiogenic effect. This is thought to be a result
from the heightened sensitivity of endothelial cells, relative
to tumor cells, to the cytotoxic effect of chemotherapies
while side effects on fast dividing hematopoietic and intes-
tinal cells are minimized [11, 12]. Cyclophosphamide also
depletes Tregs that play immunosuppressive roles within
tumors, and it has been used to facilitate adoptive immuno-
therapy [13–15]. In addition, dacarbazine, which like TMZ
produces MTIC as its active metabolic intermediate, has
been shown to upregulate natural killer group 2D
(NKG2D) ligands on melanoma cells and to sensitize them
for clearance by natural killer (NK) and CD8+ T cells in
mouse models [16]. Treatment of tumor cells with DNA-
alkylating agents can also result in their secretion of high-
mobility group box 1 cytokine, which stimulates the migra-
tion and activation of cytotoxic effector immune cells [17].
Therefore, TMZ has the potential to promote immunosti-
mulatory antitumor effects and it may achieve this at below
the standard-of-care doses, which are often derived from
dose escalation studies based on the maximum tolerated
off-target side effects rather than efficacy.
We report here a phase 1 study of mTMZ in patients with
recurrent malignant glioma, in conjunction with an explora-
tory analysis of tumor blood flow using arterial spin labeling
magnetic resonance imaging (MRI). We also measured
levels of soluble interleukin-2 receptor alpha (sIL-2Rα) and
the activated isoforms of matrix metalloproteinases (MMPs)
from patient cerebrospinal fluid (CSF) to determine whether
these potential biomarkers of immunogenicity and angio-
genesis/invasion correlate with patient outcome.
Methods
Study design and patient eligibility
This study was conducted between July 2006 and September
2011 after obtaining ethics approval from the Institutional
Review Board at Beth Israel Deaconess Medical Center. All
participants provided written informed consent for study
treatment and for publication of trial outcome. Subjects
were stratified according to a 3 × 3 factorial design based on
the histological diagnosis of either grade IV glioblastoma or
grade III malignant glioma, as well as by the dosage of
mTMZ either at 25 or 50 mg/m2/day taken continuously
for 42 days in a cycle. Subjects were enrolled if they had (i)
age ≥18, (ii) recurrent high-grade glioma histologically
confirmed either at initial diagnosis or at recurrence, (iii)
conventional involved-field radiotherapy, (iv) Karnofsky
performance score ≥60, (v) bi-dimensionally measureable
disease, (vi) no concurrent malignancy other than basal or
squamous cell carcinoma of the skin, or carcinoma in situ of
the cervix, (vii) stable dose of corticosteroid for ≥3 days, and
(viii) adequate hematologic, renal and liver functions.
Subjects were excluded if they had (i) multifocal glioma,
gliomatosis cerebri, low-grade glioma, or leptomeningeal
spread of the malignant glioma, (ii) difficulty undergoing
MRI scanning, (iii) chemotherapy, immunotherapy, or
biologic therapy within 4 weeks prior to study, (iv) poor
recovery from prior therapies, (v) poor medical risks, (vi)
difficulty recovering from any effect of major surgery, (vii)
requirement for P450 hepatic enzyme inducing anticonvul-
sant, or (viii) HIV or acquired immunodeficiency syndrome.
Treatment was continued until disease progression as
defined by Macdonald’s criteria [18] or withdrawal from the
trial. Clinical examination, conventional gadolinium-
enhanced head MRI with arterial spin labeling sequence [19],
and lumbar punctures were performed once before the first
cycle and after each subsequent cycle.
Assessment of safety and treatment outcome
Adverse events were recorded from subjects at baseline
and during follow up in the trial period. Severity was
graded according to the Common Toxicity Criteria version
3.0 and attribution was made to the study medication.
At the end of each 6-week mTMZ cycle, assessment
for response or progression was made using gadolinium-
enhanced T1-weighted images on MRI. Bi-dimensional
tumor size was measured according to the Macdonald’s
criteria [18].
Correlative studies
Blood flow into the tumor was measured by arterial spin
labeling during acquisition of anatomic MRI images in
an effort to characterize the vascular effect of mTMZ.
This technique was previously described in detail [19].
In brief, it utilizes repetitively pulsed radiofrequency and
magnetic gradient fields to achieve continuous inversion
of water. Acquisition was performed with a 1.5 s delay
after labeling to allow the labeled blood to reach the
microvasculature. Unlike contrast based perfusion stud-
ies, arterial spin labeling specifically uses tagged water to
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measure blood flow. Since water is freely diffusible
across the vasculature, arterial spin labeling allows for
an accurate quantitative assessment of blood flow that is
independent of vascular permeability.
Blood flow from arterial spin labeling images was quan-
tified as described by Jarnum et al. [20]. A region of inter-
est (ROI) was drawn that contained the malignant glioma
based on post-gadolinium T1-weighted images. The aver-
age blood flow, in absolute cc/g•min, was obtained by
computing the mean value across all voxels within that
ROI. In addition, a blood flow ratio was calculated based
on the ROI of the tumor to a corresponding ROI in the
contralateral brain to allow for comparison of the blood
flow data across multiple scans obtained over time.
Enzyme-linked immunosorbent assay (ELISA) was per-
formed on the CSF obtained from our subjects. CSF was
collected at baseline and at the end of each metronomic
cycle, stored at −80° C, and then thawed for batched ana-
lysis. DuoSet ELISA kits DY223, DY902, and DY911 were
obtained from R&D for determination of sIL-2Rα, activated
MMP-2 (aMMP-2) and activated MMP-9 (aMMP-9) levels,
respectively.
Statistics
PFS and OS curves were plotted according to the Kaplan-
Meier method [21]. The strength of correlation between
blood flow and clinical outcome, as well as between
cerebrospinal fluid biomarkers and clinical outcome, was
evaluated by linear regression. Significance was computed
and plotted using Graphpad Prism 6 software. Fold change
from baseline, if positive, was reported as the final blood
flow ratio divided by the initial blood flow ratio minus 1. If
negative, fold change was reported as the negative recipro-
cal of the final blood flow ratio divided by the initial blood
flow ratio minus 1.
Results
The demographic characteristics of the 9 subjects (6 with
glioblastomas and 3 with anaplastic gliomas) entered into
the study are listed in Table 1. Their median age was 64
(range 26–82) years and their median KPS was 70 (range
60–90). Because protocol accrual began in 2006 and
ended in 2011, all subjects had been treated with the
standard-of-care radiation with concomitant daily TMZ at
the time of their initial diagnosis. However, the number of
cycles of post-radiotherapy adjuvant TMZ received was
variable, ranging from none to 20 completed cycles prior to
enrollment. One subject with glioblastoma signed consent
for the protocol but did not receive mTMZ at 25 mg/m2/
day because of rapid clinical deterioration. Another subject
with glioblastoma underwent one cycle of mTMZ treat-
ment at 25 mg/m2/day. Four subjects received 50 mg/m2/
day of mTMZ for 1, 2, 5 and 6 cycles. Two subjects with
anaplastic gliomas (one small cell anaplastic astrocytoma
and one anaplastic oligodendroglioma) received 2 and 19+
cycles of mTMZ at 25 mg/m2/day, while a third with ana-
plastic glioma completed 8+ cycles at 50 mg/m2/day.
Safety and toxicity
mTMZ was well tolerated and, as expected, the most fre-
quent adverse events were hematological in nature (Table 2).
Grade 1 or 2 leukopenia and lymphopenia occurred in 2 sub-
jects while anemia, neutropenia and thrombocytopenia were
observed in 1 subject, but none experienced grade 3 or 4
hematological toxicity. Gastrointestinal side effects occurred
in 3 subjects, with one experienced grade 3 elevation of liver
enzyme that was resolved after discontinuation of mTMZ.
Two additional subjects had grade 1 liver dysfunction. Add-
itional minor side effects included thrush, zoster eruption
and petechial rash, which were all of grade 1 severity.
Outcome analysis
The median number of mTMZ cycles received within the
study group was 2 (range 0-19+), and the median time from
initial diagnosis to first recurrence was 5.8 (range 2.4–
128.6) months (Table 1). The number of prior adjuvant
TMZ cycles received does not appear to correlate with the
number of mTMZ cycles (Spearman correlation = −0.3914,
p = 0.3053). The median progression free survival was 8.5
(range 1.5–153.0+) months and the median overall survival
was 12.7 (range 7.1–153.0) months (Fig. 1a & 1b ). Because
6 of 9 subjects (67%) had recurrent glioblastoma, and they
compromise the largest subgroup in our cohort with simi-
lar histological characteristics, we decided to combine their
outcomes to estimate the benefit of mTMZ treatment.
Their median progression free survival was 3.1 (95% CI N/
A-8.3) months and their overall survival was 12.5 (95% CI
8.6–16.3) months (Fig. 1c & 1d).
Correlative studies
Two types of correlative analysis were performed to help
elucidate the antiangiogenesis and antitumor effects of
mTMZ. The first type consisted of arterial spin labeling
blood flow studies obtained serially in subjects at 6-week in-
tervals during anatomic MRI scanning. It is noteworthy that
there was marked variability in blood flow over time in our
cohort during treatment (Fig. 2a), with two subjects initially
experiencing a slight increase before a decrease was ob-
served while two others had a gradual but consistent decline
in blood flow. In particular, subject 5 had an increase in the
normalized blood flow ratio from 0.70 at baseline to 0.92 at
6 weeks, followed by a decrease to 0.51 at 12 weeks and
subsequently two successive increases to 0.72 and 1.53 at 18
and 24 weeks, respectively, due to a new focus of tumor
focus in the ipsilateral brain (Fig. 2b). Furthermore, subject
9 had a gradual and sustained decrease of more than 50% in
the blood flow ratio over time, from 0.91 at baseline to 0.39
at 54 weeks (Fig. 2c). These fluctuations in blood flow could
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be a result of alterations in the vascular physiology of the
tumor, mTMZ treatment-induced changes in blood flow, or
a combination of both.
Additional analyses were performed to explore the rela-
tionship between tumor blood flow and patient outcome
using (i) the baseline blood flow ratio as well as (ii) the
change in the blood flow ratio between baseline and the
first set of data (Table 3). There was no correlation between
baseline blood flow ratio and PFS (r2 = 0.2479, p = 0.3933),
baseline blood flow ratio and OS (r2 = 0.2829, p = 0.2774),
initial change in blood flow ratio and PFS (r2 = 0.1306, p =
0.5502), or initial change in blood flow ratio and OS (r2 =
0.0312, p = 0.7762). Collectively, the highly variable blood
flow characteristics in the tumor and our small patient
sample size preclude any reasonable statistical analysis.
However, we can still observe qualitative changes using
arterial spin labeling and in particular those who stayed on
therapy longest showed stable to decreasing blood flow in
the tumor over time.
CSF biomarkers relevant to the biological effects of
mTMZ were also investigated. Specifically, MMP-2 and
MMP-9 are activated during angiogenesis and glioma in-
vasion, and both of these enzymes can be measured in the
CSF. Indeed, our ELISA analyzed showed a bias toward
lower levels of aMMP-2 compared to baseline as subjects
were treated with mTMZ over time (Fig. 3a), while
aMMP-9 levels remained highly variable in the CSF des-
pite treatment (Fig. 3e). Furthermore, aMMP-2 directly
correlated with OS (r2 = 0.9698, p = 0.0152) (Fig. 3d) but
not PFS (r2 = 0.6103, p = 0.2188) (Fig. 3c), while aMMP-9
did not correlate with OS (r2 = 0.6000, p = 0.2254) (Fig. 3h)
or PFS (r2 = 0.6416, p = 0.1990) (Fig. 3g). Baseline aMMP-
2 (Fig. 3b) and aMMP-9 (Fig. 3f) did not correlate with
time to first recurrence of the malignant glioma.
Previous studies have showed that metronomic dosing
of TMZ can reduce the ratio of Treg/CD4+ cells whereas
higher doses do not, and this reduction in Tregs could po-
tentially reverse immunosuppression within the tumor
microenvironment [9]. To investigate this aspect of
mTMZ mechanism, we quantified the CSF levels of sIL-
2Rα (also known as sCD25), which is known to counteract
immune system activation in cancer patients and high
levels of this biomarker in the serum have been correlated
with poor survival [22–24]. Among our cohort with recur-
rent malignant gliomas, there was high variability in the
levels of CSF sIL-2Rα (Fig. 3i) and high levels correlated
with a shorter time from initial diagnosis to first recur-
rence (r2 = 0.9043, p = 0.0490) (Fig. 3j). Notably, the two
subjects with elevated levels of sIL-2Rα had the longest
Table 2 Adverse events from mTMZ that were tabulated during
the study period
Adverse events Severity number of patients (%)
Grade 1 & 2 Grade 3 & 4
Hematological
Anemia 1 (11%) 0
Leukopenia 2 (22%) 0
Lymphopenia 2 (22%) 0
Neutropenia 1 (11%) 0
Thrombocytopenia 1 (11%) 0
Fatigue 1 (11%) 0
Gastrointestinal
Increased alkaline phosphatase 0 0
Increased ALT 1 (11%) 1 (11%)
Increased AST 1 ( 11%) 0
Infection
Thrush 1 (11%) 0
Zoster eruption 1 (11%) 0
Skin
Petechial rash 1 (11%) 0
Table 1 Patient characteristics and outcomes
No Adjuvant TMZ
cycles








1 1 2 Glioblastoma 70 50 2.9 3.1 71.0
2 0 0 Glioblastoma 90 25 2.4 N/A 11.0
3 1 2 Small cell anaplastic
astrocytoma
70 25 2.7 7.1 7.1
4 20 1 Glioblastoma 70 25 23.3 1.5 9.7
5 2 6 Glioblastoma 70 50 5.8 9.9 12.7
6 0 19 Anaplastic
ogliodendroglioma
90 25 128.6 >107 Alive
7 13 1 Glioblastoma 70 50 18.1 1.9 12.6
8 1 5 Glioblastoma 60 50 3.6 11.4 14.4
9 0 8 Anaplastic glioma 70 50 120.0 22.9 33.7
Baseline characteristics and outcomes among subjects treated with mTMZ
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PFS (9.9 and 11.4 months) while the other two with
undetectable levels possessed the shortest PFS (1.5 and
1.9 months). There was a trend for correlation between
sIL-2Rα and OS (r2 = 0.8218, p = 0.0935) (Fig. 3l) but not
between sIL-2Rα and PFS (r2 = 0.6109, p = 0.2184) (Fig. 3k).
Discussion
Unlike the conventional schedule of TMZ at 150–200 mg/
m2/day for 5 days, mTMZ is typically given continuously at
a dose of 25 to 50 mg/m2/day. Such lower daily dosage may
not be myelotoxic enough to cause significant leukopenia
or thrombocytopenia while retaining antitumor efficacy
and, when given over a longer period of time, the cumula-
tive dose from mTMZ could be higher than the dose from
conventional schedule. In the current study, TMZ given in
metronomic doses was well tolerated by our subjects with
recurrent malignant gliomas. The side effects observed
were primarily hematological and gastrointestinal in nature,
and nearly all of them were in the grade 1 or 2 severity cat-
egory. This is consistent with findings in past phase II trials
and retrospective series where others observed mild lym-
phopenia, neutropenia, thrombocytopenia and liver enzyme
elevation [25–27].
Chronic daily dosing of cytotoxic chemotherapies have
been in use as salvage treatment in oncology. Fulton et al.
[28] reported the use of metronomic oral etoposide for re-
current malignant gliomas and noted an objective response
rate of 18% (8 of 46 patients) and a median time to tumor
progression of 8.8 weeks, while side effects consisted of
manageable neutropenia and thrombocytopenia. Compared
to pulsed intravenous administration of etoposide, metro-
nomic oral etoposide has similar or even better bioavailabil-
ity [29]. In addition, daily capecitabine is indicated for
metastatic colon cancer and taxane-refractory breast cancer
[30, 31]. Compared to intravenous 5-fluorouracil and
leucovorin, capecitabine has less frequent hematological
toxicity but more hepatic enzyme elevation, probably due
to its first pass in the liver when taken orally [31].
Multiple mechanisms likely contribute to the antitumor
efficacy of mTMZ. Our trial is the first to incorporate both
neuroimaging and CSF correlative studies to help elucidate
the underlying antitumor mechanisms of mTMZ. Arterial
spin labeling MRI was used to measure blood flow at the
site of disease and elsewhere in the brain. It is important to
note that our current method of visualization of brain
tumors relies on leakage of gadolinium from highly perme-
able vasculature into the brain parenchyma and thus this
process delays its clearance. However, malignant gliomas
are highly infiltrative and vascular breakdown is typically
not present at the invasive front of the tumor. Therefore,
gadolinium-enhanced MRI demonstrates only a part of the
tumor that has permeable vasculature. Pirzkall et al. [32]
used multivoxel MR spectroscopy to demonstrate the pres-
ence of non-enhancing gliomas in areas that has elevated
choline signals but no leakage of gadolinium. Similarly, ar-
terial spin labeling can demonstrate regions of malignant
gliomas without gadolinium enhancement, which is prob-
ably a result of the elevated metabolic demand of the tumor
Fig. 1 Treatment outcomes from mTMZ. Subjects with anaplastic glioma (black) and glioblastoma (white) and their individual (a) PFS and (b) OS are displayed
individually. Six of 9 (67%) subjects had glioblastoma and their (c) PFS was 3.1 (95% CI N/A - 8.3) months and (d) OS was 12.5 (95% CI 8.6–16.3) months
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Fig. 2 ASL-based blood flow is altered by mTMZ. a Spider plot of ASL blood flow in individual subjects. b Subject 5 had an initial increase in the
normalized blood flow ratio from 0.70 at baseline to 0.92 at 6 weeks, followed by a decrease to 0.51 at 12 weeks and subsequently two
successive increases to 0.72 and 1.53 at 18 and 24 weeks, respectively, as a result of a new focus of tumor in the ipsilateral brain (arrowhead). c
Subject 9 had a gradual and sustained decrease of more than 50% in the blood flow ratio over time, from 0.91 at baseline to 0.39 at 54 weeks
Table 3 Correlative biomarkers in subjects treated with mTMZ. Tumor blood flow was measured by arterial spin labeling (ASL) MRI
while CSF levels of aMMP-2, aMMP-9 and sIL-2α were measured by ELISA
No Number of ASL scans Tumor blood flow aMMP-2 aMMP-9 sIL-2Rα
Blood flow average



















1 2 11.7 0.98 1.08
2 2 42.4 0.99 0.99
3 2 26.0 1.35 1.31
4 2 21.8 0.80 0.64 13.7 7.0 13.2 11.0 0 0
5 5 23.4 0.70 0.88 13.9 13.4 5.7 7.2 11.3 9.7
6 18 42.2 0.92 0.90 16.7 16.7 6.6 7.3 19.5 18.1
7 2 46.3 0.68 0.88 9.7 12.5 5.9 9.2 0 3.8
8 9 17.1 0.59 0.58 13.9 15.1 11.9 8.4 18.1 21.9
9 7 13.8 0.91 0.58 14.0 11.2 4.0 3.8 0 2.5
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Fig. 3 (See legend on next page.)
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that requires increased blood flow. Furthermore, unlike
measurement of the antiangiogenesis effect of mTMZ using
cerebral blood volume maps [25], which are calculated
values that can be altered by steroid’s effect on vascular
permeability, arterial spin labeling has another advantage
because it does not require a contrast agent. Instead, this
technique utilizes magnetic field gradients and radiofre-
quency fields to label the endogenous water of blood and,
because water is freely diffusible within the brain even with-
out damage to the blood brain barrier, it allows for a quan-
titative analysis of blood flow in regions that include the
malignant glioma [19, 33]. The absolute quantification of
blood flow may be limited by regional heterogeneity of the
tumor and slight variability may appear in data acquired at
different time points. As shown by our data, a blood flow
ratio in the tumor normalized to a reference part of the
brain may reflect more accurately changes over time.
Alterations in the blood flow ratio have been detected in
some of our subjects during treatment with mTMZ. Kerbel
et al. [12, 34] demonstrated in an experimental setting that
metronomic cyclophosphamide, an alkylator similar to
temozolomide but requiring first pass hepatic metabolism
to its active agent, delayed or prevented the growth of
xenografted tumors in mice. This antitumor effect was
most likely mediated by a reduction in the circulating endo-
thelial precursor cells, which are thought to be more sensi-
tive to cytotoxic chemotherapy, and this effect is not
specific to cyclophosphamide but also other agents such as
cisplatin, vinblastine and vinorelbine [35]. However, in pa-
tients with recurrent glioblastomas treated with mTMZ
and an antiangiogenic adjuvant celecoxib, immunostaining
of CD31-positive endothelial cells of resected tumors before
treatment showed high variability in microvessel density
[36]. Furthermore, microvessel density did not correlate
with patient outcome [36]. Nevertheless, an objective re-
sponse rate of 5 to 14% and a PFS at 6 months of 17 to
57% were observed in patients treated with mTMZ, sug-
gesting other mechanisms of action may be relevant.
Invasion is a major hallmark of malignant gliomas and
antiangiogenesis therapy can bias the tumor towards an
invasive phenotype [5, 37, 38]. These invasive glioma cells
are thought to possess stem-like cellular characteristics
[39]. In this process, MMPs are activated and, in particu-
lar, the expression of MMP-2 and MMP-9 is upregulated
within the tumor microenvironment [40]. Furthermore,
both MMP-2 and MMP-9 activities can also be measured
in the CSF, and MMP-9 activity in particular was noted to
correlate with disease activity in recurrent glioblastoma
[41, 42]. We used activation isoform-specific ELISA as a
proxy for MMP-2 and MMP-9 activity within the CSF. In
our subjects, the average aMMP-9 level did not correlate
with either PFS or OS, but average aMMP-2 level did ap-
pear to correlate with OS. This may indicate that the
source of aMMP-2, which is constitutively expressed in
the brain, may come from sources other than the tumor
or the brain parenchyma. Specifically, immune cells can
also secrete MMP-2 and MMP-9, and the elevated MMP-
2 activity that correlated with OS may indicate an antitu-
mor inflammatory response as a part of innate immunity
in the host [43]. However, given the weak correlations be-
tween aMMP-2 and aMMP-9 in the CSF and outcomes, it
is not clear that mTMZ exerts an anti-angiogenic or anti-
invasive effect. In fact, the insignificant changes in metal-
loproteinases during mTMZ treatment suggest that
mTMZ may not work by an anti-angiogenic mechanism
and that immunogenic or alkylating effects may have
greater relevance.
mTMZ can modulate the immune system to elicit an
antitumor response by selective depletion of Tregs [9]. It
is notable that at doses given to our subjects that are not
cytotoxic to tumor cells, mTMZ still produced a response
rate of 14%. This antitumor effect may be the result of
Treg depletion that effectively reduces immune suppres-
sion within the tumor microenvironment [9, 10, 25–27].
Specifically, Tregs can suppress T lymphocyte activation
by inhibiting IL-2 production [44]. Indeed, a high serum
level of sIL-2Rα in patients with metastatic melanoma is
strongly correlated with poor outcomes from anti-CTLA-
4 treatment, which requires concomitant IL-2-mediated
immune activation [23]. Likewise, sIL-2Rα modulates IL-
2-mediated immune response in patients with follicular
lymphoma [24]. Using CSF, we observed that baseline sIL-
2Rα was inversely correlated with time to first recurrence
of glioblastomas prior to mTMZ treatment, and that the
two subjects having elevated baseline levels possessed the
longest PFS while the other two with undetectable levels
exhibited the shortest PFS. These data suggest a potential
contribution of T-cell biology to mTMZ benefit and that
patients with elevated CSF sIL-2Rα at baseline have more
aggressive disease but they may benefit more from the im-
munomodulatory effect of mTMZ.
In our cohort, mTMZ was well tolerated and without
serious side effects. Although gadolinium enhancement
on T1 is observed at the region of the tumor, blood flow
(See figure on previous page.)
Fig. 3 Correlative analyses of MMP-2, MMP-9 and sIL-2Rα in the CSF. (a to d) Activated MMP-2 has a bias toward lower levels when compared to
baseline during treatment with mTMZ. The mean MMP-2 level has a direct correlation with OS but not PFS. (e to h) The level of activated MMP-9
is highly variable during treatment with mTMZ, but there was no correlation with OS or PFS. (i to l) sIL-2Rα levels are also highly variable among
individual patients. Baseline sIL-2Rα level has an inverse correlation with time from initial diagnosis to first recurrence. There is a trend for correl-
ation between increased sIL-2Rα level and OS but not PFS
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as measured by arterial spin labeling showed high
variability across individuals and time, with some tumor
blood flow increased briefly before subsiding while
others showed a gradual decrease or stabilization. The
correlation of aMMP-2 with OS and baseline sIL-2Rα
with OS both suggest that mTMZ may exhibit a T-cell-
dependent immune modulatory effect in patients with
recurrent malignant gliomas.
Conclusion
mTMZ is well tolerated in our cohort with recurrent
malignant gliomas. It possesses efficacy against these tu-
mors by altering blood flow, slowing invasion and modu-
lating antitumor immune function.
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survival; PFS: Progression free survival; sIL-2Rα: Soluble interleukin-2 receptor
alpha; Tregs: Regulatory T cells
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